| |
| | Blood Safety |
 | | She urged consideration of pure recombinant factors as a national standard for all clotting factor used in hemophilia treatment, and she stressed that it was not the wish of the hemophilia community to request standards that would be to the detriment of any other treatment community. |
 | | He stated that the volume of intravenous immunoglobulin that could not be released because of Creutzfeldt-Jakob disease-related withdrawals was 186 kg in 1996 and 1066 kg in 1997 (an average dose is 25 gin). |
 | | The net available supply of intravenous immunoglobulin, based on figures compiled by Georgetown Economic Services, was 13,752 kg in 1996, 12,994 kg in 1997, and a projected 13,000 kg in 1998; exports were 2352 kg in 1996, 2663 kg in 1997, and a projected 2558 in 1998. |
| www.os.dhhs.gov /bloodsafety/summaries/sumapr98.html (4163 words) |
|